These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10207353)

  • 21. Tolcapone increases maximum concentration of levodopa.
    Müller T; Woitalla D; Schulz D; Peters S; Kuhn W; Przuntek H
    J Neural Transm (Vienna); 2000; 107(1):113-9. PubMed ID: 10809409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
    Leicht MJ; Mitchell SD
    S D J Med; 1999 Aug; 52(8):295-7. PubMed ID: 10453205
    [No Abstract]   [Full Text] [Related]  

  • 23. Mosé Da Prada and the discovery of tolcapone.
    Borroni E; Borgulya J; Zürcher G
    J Neural Transm Suppl; 1998; 52():XIII-XVI. PubMed ID: 9564601
    [No Abstract]   [Full Text] [Related]  

  • 24. Tolcapone: an efficacy and safety review (2007).
    Olanow CW; Watkins PB
    Clin Neuropharmacol; 2007; 30(5):287-94. PubMed ID: 17909307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolcapone and neurotoxicity in Parkinson's disease.
    Kuhn W; Woitalla D; Gerlach M; Russ H; Müller T
    Lancet; 1998 Oct; 352(9136):1313-4. PubMed ID: 9788488
    [No Abstract]   [Full Text] [Related]  

  • 26. COMT inhibition and safety.
    Martignoni E; Blandini F; Pacchetti C; Nappi G
    Funct Neurol; 2001; 16(4 Suppl):135-40. PubMed ID: 11996508
    [No Abstract]   [Full Text] [Related]  

  • 27. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
    Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
    Nutt JG
    Lancet; 1998 Apr; 351(9111):1221-2. PubMed ID: 9643737
    [No Abstract]   [Full Text] [Related]  

  • 31. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European Union directives on medicinal products found to be seriously defective.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1999 Mar; 18(1):3-4. PubMed ID: 10401519
    [No Abstract]   [Full Text] [Related]  

  • 34. The rise and fall of tolcapone.
    Colosimo C
    J Neurol; 1999 Oct; 246(10):880-2. PubMed ID: 10552233
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease.
    Unger MM; Reese JP; Oertel WH; Eggert KM
    Eur Neurol; 2008; 60(3):122-6. PubMed ID: 18628629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [COMT inhibition with tolcapone].
    Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolcapone withdrawn.
    Prescrire Int; 1999 Apr; 8(40):53. PubMed ID: 10848065
    [No Abstract]   [Full Text] [Related]  

  • 39. Kleptomania treated with tolcapone, a catechol-O-methyl-transferase (COMT) inhibitor.
    Grant JE
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):295-6. PubMed ID: 21062636
    [No Abstract]   [Full Text] [Related]  

  • 40. [Akathisia secondary to tolcapone. Report of a case].
    Colorado-Ochoa H
    Gac Med Mex; 2000; 136(5):505-9. PubMed ID: 11080934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.